Event in Progress:
Discover the latest content that has just been published on Research Tree
This is the easier task but staying ahead is a tougher one. And, for a tough quarter, management guided in the call that, due to the steep energy price increases in Q1, these would have to be passed on with a one quarter time lag. Another core topic was Lanxess’s preparedness, when it comes to potential embargos / sanctions and other impacts from the Ukraine war. The financials were no big surprise after the release some days ago at first sight, but divulged some interesting details.
Companies: LANXESS AG
AlphaValue
Lanxess’ preliminary figures were above consensus expectations (sales: +8.5%; adjusted EBITDA: +6.8%). This positive development is anticipated to stem from the changes in contract terms allowing for a more stringent roll-over of higher energy prices. Despite this head start, the management made no changes to the guidance.
Lanxess reported some moderate impact on profitability after the strong portfolio rotation. Rightly, the company became a stronger player in the specialities chemicals arena, which gives Lanxess’ EBITDA a certain robustness as it should be clear that margins are not carved in stone. Lanxess reported a good set of figures, strongly beating our top-line expectations (+6.1%) and EBITDA was well ahead. Consensus was partly beaten (top line: +3.2%; adjusted EBTDA: 0%). Current tensions prevented
Despite the consensus-beating Q3 figures, the positive Lanxess’ share price performance has taken a breather. The management flagged a more difficult Q4 and guided to the lower end of the unchanged corridor. We share the management’s view that the factors mentioned will weigh on the figures despite their being part of the business model and the fact that they should be temporary.
Lanxess has taken the opportunity to acquire the Microbial Control business from a leading player in the flavour and fragrance business, which had seen three owners in three years. But this is quite an expensive opportunity once the synergies are stripped out. It looks as if management has some inner understanding of how profitability could be increased and how to stop the personnel drain.
Lanxess’ reported figures were, all in all, quite a re-bounce story, but the operating CF was severely hit by the strong NWC outflow. This was mainly a result of the higher inventories. Nevertheless, the company has shown its resilience and its determination to cushion the negative effects from higher raw material prices. Consensus was beaten by +8.9% at the top line and by +3.9% at EBITDA pre level. The guidance adjustment stemmed mainly from acquisitions’ contributions.
Lanxess has undergone quite a substantial and lengthy restructuring phase to make the company more resilient. The proof it has worked was shown in 2020, but street expectations have also risen. The reported figures were above these, but the beat was quite tiny compared to its peers. Looking at the company’s own expectations, they were at the upper end. ‘Selling’ the narrowing of the previous guidance range as a rise, looks like a marketing gimmick.
One could get the impression that Consumer Protection ‘disinfected’ the group as the company came quite well through the pandemic. Adjusted EBITDA was down 15%, which looks like next to nothing compared to the previous crisis (e.g. the one in 2012/13). The fair answer is that Lanxess looks totally different and the far lower share of cyclical businesses helped to sustain profitability. Our estimates have been clearly beaten on the top line and less pronounced on the profitability levels. Consen
There were some rumours a few weeks ago that Lanxess might be in takeover discussions with the PE firm American Securities. This became a reality today. Contrary to the typical analyst’s reflex, we value the deal as not an expensive one despite management’s strong reference to synergies. In our view, the acquisition of Emerald Kalama makes a lot of sense and fosters Lanxess’s position in its new strong playing field of Consumer Protection, which will absorb ~75% of the quite profitable sales.
Lanxess had a tough Q3. All divisions, except Consumer Protection, suffered from a weaker top line (prices and volumes), which also weighed on margins. However, these divisions saw some recovery with different dynamics. We value the narrowing of the guidance as management’s realistic view on recent developments. The reported figures slightly missed our strong expectations, but fitted with consensus.
Companies: LXS1 LNXSF LXS LXS LXSEUR
Lanxess’ cash pile remained quite high and the pattern of NWC flows gave us no clear indications. Q2 net earnings were positively impacted by the divestment result from the 40% stake sale in Currenta. The group was primarily hit by the lower volumes, except for Consumer Protection. Reported figures were above our expectations, but broadly meet street expectations.
We see management’s actions and the reference to its achievements of the measures made on the portfolio as a bit disconnected. On one hand, Lanxess has great liquidity in a crisis situation since the spin-out from Bayer and, on other hand, it highlighted a more balanced portfolio and lower exposure to the automotive industry. However, it was a smart move to sponge up cash. The Q1 figures came in above our expectations and beat the street’s estimates.
Against the background of the looming COVID-19-driven panic, the Saudi Arabian show-of-force and a rising likelihood of a global recession, we believe Lanxess’s 2020 guidance does not include all the negative impacts as some are really quite recent. We appreciate management’s efforts to guide for potential COVID-19 effects. Lanxess’s figures came in fully in line with our operational expectations, especially on the profitability levels that we were focusing on. Consensus was partly beaten and it
Lanxess seems to have left the path of strong cyclicality and the respective impact on profitability. Nevertheless, the company could not completely decouple from the economic environment as Engineering Materials recorded lower margins. Reported figures were stronger than expected, especially on the profitability line, but full matched the street’s expectations.
Back in 2014, prior to Mr Zachert taking over, the current harsh environment would have had a significantly negative impact on the figures. For the current-day Lanxess, these negative impacts were not that strong as prices remained quite stable in Q2. The reported figures were a notch above our expectations and in line with consensus.
Research Tree provides access to ongoing research coverage, media content and regulatory news on LANXESS AG. We currently have 29 research reports from 2 professional analysts.
The FY24 year-end update is very upbeat signalling trading being materially ahead of expectations, with a better-than-expected profit out turn and stronger cash generation. It continues to strengthen margins through efficiencies and investment in modern equipment. The order book remains close to record levels providing a robust view of future forecasts. In FY24E we upgrade EPS by 11% and in FY25E a significant upgrade of 27.6%. It looks capable of declaring a dividend in FY25 as well as manageme
Companies: Renold plc
Cavendish
Companies: BILN ELCO NXQ CUSN ATG
Another Good Year of Diversified Growth with More to Come in 2024 CCapital have released their Q1 operating results. Overall, revenue has come in slightly lower than expected at $80.2m vs TamE of $85.9m but is largely tracking in line with our FY24 annual estimate and we note the company has maintained guidance. Drilling revenue for this quarter was impacted by a fall in utilisaztion rates as well as general remobilisation geographically but we expect a strong recovery throughout the year as k
Companies: Capital Limited
Tamesis Partners
FY23 results show very strong growth over FY22, driven by strong Structural Steel activity, with results slightly ahead of upgraded profit expectations, while stronger than expected cash flow resulted in an unexpectedly generous dividend of 33p (offering a FY23 yield of 7.0%). The group now has net cash of £22.1m and is debt free and is therefore in a strong position for potential M&A activity. Following the recent £90m of new orders to increase the order book to record levels we conservatively
Companies: Billington Holdings Plc
Plant Health Care announced it has signed a distribution agreement with AMVAC, an American Vanguard Company, to support commercialisation of novel fertiliser products incorporating Plant Health Care's Harpinαβ in China starting in 2024. The novel product combines Harpinαβ technology with an AMVAC fertiliser and is expected to help growers improve crop quality and yield as part of an integrated and environmentally responsible crop production programme. AMVAC continues to evaluate Plant Health Car
Companies: Plant Health Care PLC
Companies: 88E RNO TRIN KRM EXR BOOM
discoverIE’s March year-end update confirms a strong operational performance in challenging markets. Following two years when sales increased by +48%, FY 2024 Group sales were +1% ahead of 2023 at CER (reported -3%) driven by a +2% contribution from acquisitions and organic -1%. As expected, organic growth returned in the later part of the year (Q4 +2%, +11% sequentially) and the order book has reverted to normalised levels of c.4.5 months’ sales, which – combined with a continuing strong pipeli
Companies: discoverIE Group PLC
Severfield’s trading update indicates that FY23 results are expected to slightly exceed market expectations and the company ends the year with a record UK and Europe order book. Furthermore, with a positive trading outlook and net debt coming in lower than expected, Severfield has announced a £10m share buyback, highlighting the cash-generative nature of the company and management’s confidence in its position. The stock trades on an FY25 P/E of less than 6x and yields 7%, which we believe appear
Companies: Severfield Plc
Edison
Companies: Iofina plc
Canaccord Genuity
Companies: PLL TLG HZM SAV KAV KP2 SVML
SP Angel
Acquisitions have been an important element of Severfield management’s growth strategy, with the aim of adding new products, sectors and regions to what we have identified as exciting long-term organic opportunities. In this Spotlight report, we focus on the group’s targeted M&A approach, highlighting three significant deals.
Progressive Equity Research
Liberum
Invinity’s update on discussions with strategic investors reveals interest from multiple parties. While this has slightly delayed finalising an agreement it increases the potential for a better outcome. Although details are unknown at this stage, we think there is enough in the statement to be comfortable that any agreements will be consistent with the company’s strategy of growing market share in core markets and using a licencing and royalty model in other markets.
Companies: Invinity Energy Systems PLC
Longspur Clean Energy
Severfield’s full-year results to March will be ‘slightly above’ the Board’s expectations, according to today’s trading update, with net debt significantly better. We maintain our PBT estimates for both forecast years, which are ahead of consensus, but reduce our net debt for FY24E. Record orders were boosted by the steel specialist’s European operations, after last year’s Voortman acquisition, while the Indian JV has seen ‘another step up in profitability’. The group has also launched its first
Companies: ATOME PLC
Share: